Integra LifeSciences - IART Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IART shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IART, but not buy additional shares or sell existing shares.
View IART analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year target prices for Integra LifeSciences' stock. Their IART share price forecasts range from $50.00 to $87.00. On average, they predict the company's share price to reach $65.43 in the next year. This suggests a possible upside of 50.1% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $66.99 at the beginning of the year. Since then, IART stock has decreased by 34.9% and is now trading at $43.59.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our IART earnings forecast.

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its earnings results on Wednesday, July, 27th. The life sciences company reported $0.82 earnings per share for the quarter, beating analysts' consensus estimates of $0.80 by $0.02. The life sciences company had revenue of $397.82 million for the quarter, compared to analyst estimates of $394.54 million. Integra LifeSciences had a net margin of 10.61% and a trailing twelve-month return on equity of 16.72%.

Integra LifeSciences shares split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences issued an update on its third quarter 2022 earnings guidance on Tuesday, September, 20th. The company provided EPS guidance of $0.69-$0.73 for the period, compared to the consensus EPS estimate of $0.80. The company issued revenue guidance of $374.00 million-$382.00 million, compared to the consensus revenue estimate of $387.79 million.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Integra LifeSciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Champlain Investment Partners LLC (6.53%), Clearbridge Investments LLC (3.06%), Cooke & Bieler LP (3.00%), Goldman Sachs Group Inc. (1.76%), Northern Trust Corp (0.78%) and Millennium Management LLC (0.55%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Peter J Arduini, Raymond G Murphy, Richard E Caruso, Stuart Essig and Tru St Partnership, LP.
View institutional ownership trends.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IART stock can currently be purchased for approximately $43.59.

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.64 billion and generates $1.54 billion in revenue each year. The life sciences company earns $169.07 million in net income (profit) each year or $1.97 on an earnings per share basis.

The company employs 3,800 workers across the globe.

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.